AEs related to HBI0101 therapy
| Event and grade . | Total (N = 50) . |
|---|---|
| CRS | |
| Any grade, n (%) | 48 (96%) |
| 1 | 17 (34%) |
| 2 | 24 (48%) |
| 3 | 7 (14%) |
| CRS start day, median (range) | 0 (0-4) |
| CRS duration days, median (range) | 1 (1-7) |
| Tocilizumab use, n (%) | 40 (80%) |
| Tocilizumab doses, median (range) | 1 (0-4) |
| Steroids use, n (%) | 8 (16%) |
| Vasopressors, n (%) | 7 (14%) |
| Neurotoxicity | |
| Any, n (%) | 3 (6%) |
| Neurologic deterioration (delirium), n (%) | 1 (2%) |
| ICANS (grade 1-2), n (%) | 2 (4%) |
| ICANS start day, median (range) | 2 (2-2) |
| ICANS duration, median (range), d | 2.5 (2-3) |
| Hematologic toxicity ≤28 d | |
| Neutropenia, n (%) | |
| Any grade | 49 (98%) |
| Grade 3-4 | 49 (98%) |
| Thrombocytopenia, n (%) | |
| Any grade | 36 (72%) |
| Grade 3-4 | 27 (54%) |
| Anemia, n (%) | |
| Any grade | 44 (88%) |
| Grade 3-4 | 31 (62%) |
| Lymphopenia, n (%) | |
| Any grade | 50 (100%) |
| Grade 3-4 | 50 (100%) |
| Febrile neutropenia, n (%) | |
| Any grade | 36 (72%) |
| Grade 3-4 | 36 (72%) |
| Supportive care | |
| G-CSF, n (%) | 32 (64%) |
| Blood transfusion, n (%) | 14 (28%) |
| Platelet transfusion, n (%) | 10 (20%) |
| Nonhematologic toxicity ≤28 d, n (%) | |
| Renal failure | |
| Any grade | 9 (18%) |
| Grade 1 | 8 (16%) |
| Grade 2 | 1 (2%) |
| E/LFT | |
| Any grade | 10 (20%) |
| Grade 1 | 7 (14%) |
| Grade 2 | 2 (4%) |
| Grade 3 | 1 (2%) |
| HLH-like | 4 (8%) |
| Bacteremia | 4 (8%) |
| Other infections | 5 (10%) |
| Hospitalization stay median (d) | 24 (14-55) |
| Event and grade . | Total (N = 50) . |
|---|---|
| CRS | |
| Any grade, n (%) | 48 (96%) |
| 1 | 17 (34%) |
| 2 | 24 (48%) |
| 3 | 7 (14%) |
| CRS start day, median (range) | 0 (0-4) |
| CRS duration days, median (range) | 1 (1-7) |
| Tocilizumab use, n (%) | 40 (80%) |
| Tocilizumab doses, median (range) | 1 (0-4) |
| Steroids use, n (%) | 8 (16%) |
| Vasopressors, n (%) | 7 (14%) |
| Neurotoxicity | |
| Any, n (%) | 3 (6%) |
| Neurologic deterioration (delirium), n (%) | 1 (2%) |
| ICANS (grade 1-2), n (%) | 2 (4%) |
| ICANS start day, median (range) | 2 (2-2) |
| ICANS duration, median (range), d | 2.5 (2-3) |
| Hematologic toxicity ≤28 d | |
| Neutropenia, n (%) | |
| Any grade | 49 (98%) |
| Grade 3-4 | 49 (98%) |
| Thrombocytopenia, n (%) | |
| Any grade | 36 (72%) |
| Grade 3-4 | 27 (54%) |
| Anemia, n (%) | |
| Any grade | 44 (88%) |
| Grade 3-4 | 31 (62%) |
| Lymphopenia, n (%) | |
| Any grade | 50 (100%) |
| Grade 3-4 | 50 (100%) |
| Febrile neutropenia, n (%) | |
| Any grade | 36 (72%) |
| Grade 3-4 | 36 (72%) |
| Supportive care | |
| G-CSF, n (%) | 32 (64%) |
| Blood transfusion, n (%) | 14 (28%) |
| Platelet transfusion, n (%) | 10 (20%) |
| Nonhematologic toxicity ≤28 d, n (%) | |
| Renal failure | |
| Any grade | 9 (18%) |
| Grade 1 | 8 (16%) |
| Grade 2 | 1 (2%) |
| E/LFT | |
| Any grade | 10 (20%) |
| Grade 1 | 7 (14%) |
| Grade 2 | 2 (4%) |
| Grade 3 | 1 (2%) |
| HLH-like | 4 (8%) |
| Bacteremia | 4 (8%) |
| Other infections | 5 (10%) |
| Hospitalization stay median (d) | 24 (14-55) |
CMV, cytomegalovirus; E/LFT, electrolytes or liver function tests; G-CSF, granulocyte colony-stimulating factor; HLH-like, hemophagocytic lymphohistiocytosis-like syndrome; RSV, respiratory syncytial virus.